IS5125A - Súlfamíð málmpróteassa hindrar - Google Patents

Súlfamíð málmpróteassa hindrar

Info

Publication number
IS5125A
IS5125A IS5125A IS5125A IS5125A IS 5125 A IS5125 A IS 5125A IS 5125 A IS5125 A IS 5125A IS 5125 A IS5125 A IS 5125A IS 5125 A IS5125 A IS 5125A
Authority
IS
Iceland
Prior art keywords
sulfamide
metal protease
protease inhibits
inhibits
metal
Prior art date
Application number
IS5125A
Other languages
English (en)
Inventor
Allen Broka Chris
Allen Campbell Jeffrey
Lucas Castelhano Arlindo
Jeffrey Chen Jian
Than Hendricks Robert
Joseph Melnick Michael
Adrian Murray Walker Keith
Original Assignee
F. Hoffmann-La Roche Ag
Agouron Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26713422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5125(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag, Agouron Pharmaceuticals Inc. filed Critical F. Hoffmann-La Roche Ag
Publication of IS5125A publication Critical patent/IS5125A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Detergent Compositions (AREA)
IS5125A 1997-01-23 1999-07-22 Súlfamíð málmpróteassa hindrar IS5125A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3671497P 1997-01-23 1997-01-23
US6220997P 1997-10-16 1997-10-16
PCT/EP1998/000180 WO1998032748A1 (en) 1997-01-23 1998-01-14 Sulfamide-metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
IS5125A true IS5125A (is) 1999-07-22

Family

ID=26713422

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5125A IS5125A (is) 1997-01-23 1999-07-22 Súlfamíð málmpróteassa hindrar

Country Status (35)

Country Link
EP (1) EP0958287B2 (is)
JP (1) JP3563411B2 (is)
KR (1) KR100377696B1 (is)
CN (1) CN1093125C (is)
AR (1) AR011425A1 (is)
AT (1) ATE223909T1 (is)
AU (1) AU730127B2 (is)
BG (1) BG103586A (is)
BR (1) BR9807508A (is)
CA (1) CA2278694C (is)
DE (2) DE69807845T2 (is)
DK (1) DK0958287T3 (is)
EA (1) EA002810B1 (is)
ES (2) ES2183331T3 (is)
FR (1) FR2758559A1 (is)
GB (1) GB2321641B (is)
HR (1) HRP980036A2 (is)
HU (1) HUP0000941A3 (is)
ID (1) ID22849A (is)
IL (1) IL130802A0 (is)
IS (1) IS5125A (is)
IT (1) IT1298163B1 (is)
MA (1) MA26467A1 (is)
NO (1) NO313635B1 (is)
NZ (1) NZ336625A (is)
OA (1) OA11078A (is)
PA (1) PA8445301A1 (is)
PE (1) PE57399A1 (is)
PL (1) PL334846A1 (is)
PT (1) PT958287E (is)
TN (1) TNSN98012A1 (is)
TR (1) TR199901765T2 (is)
UY (1) UY24854A1 (is)
WO (1) WO1998032748A1 (is)
YU (1) YU34599A (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
JP2003501414A (ja) 1999-06-04 2003-01-14 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤
TR200200410T2 (tr) 1999-08-18 2002-06-21 Warner-Lambert Company Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri.
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
JP2003524007A (ja) * 2000-02-21 2003-08-12 アストラゼネカ・アクチエボラーグ アリールピペラジン類およびそれらのメタロプロテイナーゼ阻害剤（ｍｍｐ）としての使用
EP1261590B1 (en) * 2000-02-21 2012-04-11 AstraZeneca AB Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
US6495358B1 (en) * 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
EP1288199A4 (en) * 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
ATE399012T1 (de) * 2002-04-03 2008-07-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7629341B2 (en) * 2002-06-12 2009-12-08 Symphony Evolution, Inc. Human ADAM-10 inhibitors
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
RU2395503C2 (ru) * 2004-05-19 2010-07-27 Зольвай Фармасьютиклз Гмбх Лекарственные средства, содержащие n-сульфамоил-n'-арилпиперазины, предназначенные для профилактики или лечения ожирения и связанных с ним состояний
TW200626138A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
DE102004060229A1 (de) * 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
WO2007102392A1 (ja) * 2006-03-03 2007-09-13 Shionogi & Co., Ltd. Ｍｍｐ－１３選択的阻害剤
WO2008053913A1 (en) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Sulfonylurea derivative capable of selectively inhibiting mmp-13
WO2008147764A1 (en) * 2007-05-23 2008-12-04 Array Biopharma, Inc. Mmp inhibitors and methods of use thereof
US9920002B2 (en) 2007-10-12 2018-03-20 Basf Se Methods for producing sulfonic acid diamides
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
CA2768466C (en) * 2009-07-22 2018-08-14 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2012170867A1 (en) * 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
JP6507267B2 (ja) 2015-05-22 2019-04-24 チョン クン ダン ファーマシューティカル コーポレーション 選択的ヒストンデアセチラーゼ阻害剤としてのヘテロ環状アルキル誘導体化合物及びこれを含有する薬剤学的組成物
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH617318A5 (en) † 1975-09-30 1980-05-30 Ciba Geigy Ag Microbicidal composition.
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
PL178747B1 (pl) † 1994-05-04 2000-06-30 Novartis Ag Pochodne amidowe alfa-aminokwasów
DE19507447A1 (de) † 1995-03-03 1996-09-05 Vitronic Dr Ing Stein Bildvera Verfahren und Schaltung zum Erfassen und Weiterleiten von Videobilddaten in einem PC
KR100475206B1 (ko) * 1995-11-13 2005-12-16 훽스트 악티엔게젤샤프트 사이클릭및헤테로사이클릭N-치환된α-이미노하이드록삼산및카복실산
ES2183905T3 (es) * 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
DK0958287T3 (da) 2003-01-20
KR100377696B1 (ko) 2003-03-29
ID22849A (id) 1999-12-09
ES2136037B1 (es) 2000-11-16
PL334846A1 (en) 2000-03-27
CN1093125C (zh) 2002-10-23
BG103586A (bg) 2000-03-31
EA199900643A1 (ru) 2000-04-24
AU6614098A (en) 1998-08-18
AR011425A1 (es) 2000-08-16
DE19802350A1 (de) 1998-07-30
ATE223909T1 (de) 2002-09-15
PT958287E (pt) 2002-12-31
NZ336625A (en) 2001-04-27
GB2321641A (en) 1998-08-05
HUP0000941A2 (hu) 2001-04-28
NO993587L (no) 1999-09-22
PA8445301A1 (es) 2001-07-31
CN1250445A (zh) 2000-04-12
CA2278694A1 (en) 1998-07-30
WO1998032748A1 (en) 1998-07-30
EP0958287B2 (en) 2008-04-09
NO993587D0 (no) 1999-07-22
CA2278694C (en) 2006-09-26
KR20000070398A (ko) 2000-11-25
YU34599A (sh) 2002-03-18
ES2136037A1 (es) 1999-11-01
ITMI980091A1 (it) 1999-07-20
BR9807508A (pt) 2000-03-21
DE69807845T2 (de) 2003-06-05
EP0958287A1 (en) 1999-11-24
HRP980036A2 (en) 1998-12-31
TNSN98012A1 (fr) 2005-03-15
DE69807845D1 (de) 2002-10-17
FR2758559A1 (fr) 1998-07-24
NO313635B1 (no) 2002-11-04
PE57399A1 (es) 1999-06-25
GB2321641B (en) 2001-04-04
EP0958287B1 (en) 2002-09-11
ES2183331T3 (es) 2003-03-16
EA002810B1 (ru) 2002-10-31
JP3563411B2 (ja) 2004-09-08
JP2001523222A (ja) 2001-11-20
UY24854A1 (es) 2000-12-29
HUP0000941A3 (en) 2002-06-28
GB9801393D0 (en) 1998-03-18
OA11078A (en) 2003-03-17
MA26467A1 (fr) 2004-12-20
IT1298163B1 (it) 1999-12-20
IL130802A0 (en) 2001-01-28
TR199901765T2 (xx) 1999-10-21
AU730127B2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
IS5125A (is) Súlfamíð málmpróteassa hindrar
IS6164A (is) Málmpróteasa latar
NO995433D0 (no) Protease-inhibitorer
ID25897A (id) Variant-variant protease tersubstitusi banyak
ID29885A (id) Penghambat serina protease
ID24410A (id) Protease alkalin
ID20976A (id) Popok sekali pakai
ID21018A (id) Popok sekali pakai
NO990760D0 (no) 1,4-heterocykliske metallproteaseinhibitorer
ID20043A (id) Popok sekali pakai
ID21602A (id) Popok sekali pakai
NO20012980D0 (no) Proteaseinhibitorer
DE69831181D1 (de) Positionsbestimmung
MA24298A1 (fr) Inhibiteurs de protease.
ID20975A (id) Popok sekali pakai
DK0979240T3 (da) Serinproteaseinhibitor
ID21197A (id) Popok sekali pakai
DE69812454D1 (de) Metalldichtung
NO995435D0 (no) Protease-inhibitorer
NO20000857L (no) Blandeapparat
NO995434L (no) Proteaseinhibitorer
NO995268D0 (no) Proteaseinhibitorer
EP1005862A4 (en) ANTI-CHLAMYDIA MEDIUM
DE59806260D1 (de) Lasthalteventil
NO995147D0 (no) Kontrastmidler